INS and latent autoimmune diabetes in adults: In phase I and II studies, an alum-formulated vaccine (Diamyd) has shown to be safe, and in a dose-finding study in LADA patients, 20 mcg of Diamyd has been given subcutaneously 1 month apart, indicating the preservation of residual insulin secretion (125, 126).